Is This a Big Opportunity for Diagnostic Test Developers?

Since the inception of this blog over 4 years ago, one of the key topics has been companion diagnostic testing for cytochrome p450 (CYP) mutations. Indeed this was the topic of the very first post. Testing for these mutations is increasing rapidly, but CYPs remain in...

First-Ever Rankings: Top 25 Companies In Precision Medicine

Thanks to one of my LinkedIn contacts, I was introduced to a newly released “scorecard” that ranks pharmaceutical and biotechnology companies based on their precision medicine efforts. In essence, the organizations who made the cut are the ones moving precision...

73% Growth in the Use of Companion Diagnostic Biomarkers

– Metabolism biomarker testing dominates companion diagnostic (CDx) use – There is significant variability in reimbursement trends from state-to-state for CDx biomarkers – Rejected claims for CDx biomarker testing dropped by almost a third from 2013...